OBJECTIVE: Amniotic fluid embolism (AFE) induces respiratory compromise or cardiopulmonary arrest, following maternal death in most of the cases. Recently, the pathophysiology of AFE has been considered to be associated with anaphylactoid reaction, which includes mast cell degranulation and complement system activation, however, the details are still unknown. Our objective is to investigate the evidence of anaphylactoid reaction in lung. STUDY DESIGN: Our institution started a Japanese AFE registry program in 2003. Many specimens including blood, uterine and lung tissues have been delivered for further analysis. We investigated lung tissues of autopsy cases which were diagnosed as AFE from 2010 to 2017 with pathologic findings. As a control, lung tissues from maternal dead cases due to pulmonary thromboembolism (PTE) were also studied. We stained each tissue with hematoxylin-eosin, alcian blue (AlBl), and immunohistochemistry including zinc coproporphyrin-1 (ZnCP-1), cytokeratin (CK), C5a receptor (C5aR), and tryptase. RESULTS: The number of cases was nine and two in AFE and PTE respectively, and each median time from the onset to death was 191 and 107 minutes. All AFE cases had any amniotic fluid components detected by AlBl, ZnCP-1, and CK in pulmonary artery. We found degranulated mast cells, i.e., halo signs around cells, along with bronchiolar submucosal muscle layer and pulmonary artery in eight of 9 AFE cases, coincided with C5aR expression involving inflammatory cells except two. On the other hands, PTE cases had no signs of degranulated mast cells and C5aR. CONCLUSION: From the viewpoint of immune system, the pathophysiology of AFE may include two types; mostly anaphylactoid reaction. The incidence of AFE by embolization of amniotic fluid components could be lower than that of we had expected. The treatments of intravenous or even intratracheal adrenaline administration in the early stage and some agents which suppress activated complement system such as C1 inhibitor can be candidates of treatment for this fatal disease.
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